News from 84th European Atherosclerosis Congress

Click here to invite colleagues
to join the Forum for FREE

4th Meeting of the PCSK9 Forum Editorial Board

News from 84th European Atherosclerosis Congress
29 May - 1 June, Innsbruck, Austria

Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?

A new study from the University of Copenhagen, Denmark implicates raised levels of plasma levels of lipoprotein(a) as the second most frequent cause of clinical familial hypercholesterolaemia (FH, inherited high cholesterol). Professor Derick Raal (University of the Witwatersrand, Johannesburg, South Africa) discusses the implications of the study for clinicians.

Read the report and watch the video »

Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?

Clinical Latebreaker shows mixed results with novel agents in homozygous FH

There were encouraging results with evinacumab (REGN1500), a human monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3) in a proof-of-concept study, and news that an affitope-based anti-PCSK9 vaccine (AT04A) has now progressed to clinical development.

Read the report »

PCSK9 inhibitors in the clinic: New analyses provide clarification on long-term treatment issues

Answers questions about adherence, extent of statin down-titration and efficacy with moderate or high-intensity statin treatment.

Read the report »

In other news

International Atherosclerosis Society consensus statement on severe familial hypercholesterolaemia.

In this new statement, the International Atherosclerosis Society (IAS) has placed phenotype at the heart of management strategies for severe familial hypercholesterolaemia.

Read the report and watch the video »

New and updated edition of our popular therapeutic guide

A second edition of the free introductory guide: PCSK9 Inhibition - New Therapies in Cardiovascular Risk Reduction is now available on the Forum’s website. This very popular book has been updated with the latest information discussing the biology and therapeutic potential of PCSK9 inhibition.

As you know, this downloadable e-book is freely available to all registered members of the Forum.

Read online » Download now »

Forward to colleagues »

Click here to invite colleagues to join FREE

Questions & Answers

Inhibition of PCSK9 offers the real possibility of improved management of high-risk patients.

Read the full answer and other questions on the PCSK9 Forum »

Like us on Facebook

For the latest updates, PCSK9 news and analysis.

Hot topics, news and conference reports.

YouTube Channel

For videos, interviews and webcasts from leading experts.

Educational Partners
and Supporters